VEGF-specific short hairpin RNA-expressing oncolytic adenovirus elicits potent inhibition of angiogenesis and tumor growth

Molecular Therapy

Volumn 15, Issue 2, 2007, Pages 295-302

  Yoo, Ji Young ^a   Kim, Joo Hang ^a   Kwon, Young Guen ^b   Kim, Eok Cheon ^b   Kim, Nam Kyu ^a   Choi, Hye Jin ^a   Yun, Chae Ok ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

E1A PROTEIN; E1B PROTEIN; MATRIGEL; MESSENGER RNA; ONCOLYTIC ADENOVIRUS; SHORT HAIRPIN RNA; VASCULOTROPIN;

ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC GENE THERAPY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GENE THERAPY; CANCER SURVIVAL; CONTROLLED STUDY; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; ONCOLYTIC VIROTHERAPY; PROTEIN EXPRESSION; PROTEIN TARGETING; RNA INTERFERENCE; TUMOR GROWTH; TUMOR VASCULARIZATION; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALS; CELL LINE; CELL LINE, TUMOR; GENETIC VECTORS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, NUDE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; RNA INTERFERENCE; RNA, SMALL INTERFERING; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ADENOVIRIDAE;

EID: 33846334835     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/sj.mt.6300023     Document Type: Article

References (36)

1. Kim, KJ et al. (1993). Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362: 841-844.
2. Yancopoulos, GD, Davis, S, Gale, NW, Rudge, JS, Wiegand, SJ and Holash, J (2000). Vascular-specific growth factors and blood vessel formation. Nature 407: 242-248.
3. Wang, Y, Fei, D, Vanderlaan, M and Song, A (2004). Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis 7: 335-345.
4. Ellis, LM (2005). Bevacizumab. Nat Rev Drug Discov (Suppl): S8-S9.
5. Zakarija, A and Soff, G (2005). Update on angiogenesis inhibitors. Curr Opin Oncol 17: 578-583.
6. Arora, A and Scholar, EM (2005). Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther 315: 971-979.
7. Lou, TF, Gray, CW and Gray, DM (2003). The reduction of Raf-1 protein by phosphorothioate ODNs and siRNAs targeted to the same two mRNA sequences. Oligonucleotides 13: 313-324.
8. Wacheck, V et al. (2003). Small interfering RNA targeting bcl-2 sensitizes malignant melanoma. Oligonucleotides 13: 393-400.
9. Wannenes, F, Ciafre, SA, Niola, F, Frajese, G and Farace, MG (2005). Vector-based RNA interference against vascular endothelial growth factor-A significantly limits vascularization and growth of prostate cancer in vivo. Cancer Gene Ther 12: 926-934.
10. Azkur, AK, Kim, B, Suvas, S, Lee, Y, Kumaraguru, U and Rouse, BT (2005). Blocking mouse MMP-9 production in tumor cells and mouse cornea by short hairpin (sh) RNA encoding plasmids. Oligonucleotides 15: 72-84.
11. Spankuch, B, Matthess, Y, Knecht, R, Zimmer, B, Kaufmann, M and Strebhardt, K (2004). Cancer inhibition in nude mice after systemic application of U6 promoter-driven short hairpin RNAs against PLK1. J Natl Cancer Inst 96: 862-872.
12. Brummelkamp, TR, Bernards, R and Agami, R (2002). A system for stable expression of short interfering RNAs in mammalian cells. Science 296: 550-553.
13. Ganly, I et al. (2000). A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin Cancer Res 6: 798-806.
14. Heise, C, Ganly, I, Kim, YT, Sampson-Johannes, A, Brown, R and Kim, D (2000). Efficacy of a replication-selective adenovirus against ovarian carcinomatosis is dependent on tumor burden, viral replication and p53 status. Gene Ther 7: 1925-1929.
15. Khuri, FR et al. (2000). A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 6: 879-885.
16. Kirn, D (2001). Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: What have we learned? Gene Ther 8: 89-98.
17. Kirn, D (2001). Oncolytic virotherapy for cancer with the adenovirus dl1520 (Onyx-015): Results of phase I and II trials. Expert Opin Biol Ther 1: 525-538.
18. Hermiston, TW and Kuhn, I (2002). Armed therapeutic viruses: Strategies and challenges to arming oncolytic viruses with therapeutic genes. Cancer Gene Ther 9: 1022-1035.
19. Saito, Y et al. (2006). Oncolytic replication-competent adenovirus suppresses tumor angiogenesis through preserved E1A region. Cancer Gene Ther 13: 242-252.
20. Shao, R, Xia, W and Hung, MC (2000). Inhibition of angiogenesis and induction of apoptosis are involved in E1A-mediated bystander effect and tumor suppression. Cancer Res 60: 3123-3126.
21. Zhou, Z, Zhou, RR, Guan, H, Bucana, CD and Kleinerman, ES (2003). E1A gene therapy inhibits angiogenesis in a Ewing's sarcoma animal model. Mol Cancer Ther 2: 1313-1319.
22. Hoeben, A, Landuyt, B, Highley, MS, Wildiers, H, Van Oosterom, AT and De Bruijn, EA (2004). Vascular endothelial growth factor and angiogenesis. Pharmacol Rev 56: 549-580.
23. Takei, Y, Kadomatsu, K, Yuzawa, Y, Matsuo, S and Muramatsu, T (2004). A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics. Cancer Res 64: 3365-3370.
24. Byrne, AM, Bouchier-Hayes, DJ and Harmey, JH (2005). Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF). J Cell Mol Med 9: 777-794.
25. Thorne, SH, Tam, BY, Kim, DH, Contag, CH and Kuo, CJ (2006). Selective intratumoral amplification of an antiangiogenic vector by an oncolytic virus produces enhanced antivascular and anti-tumor efficacy. Mol Ther 13: 938-946.
26. Folkman, J and Shing, Y (1992). Angiogenesis. J Biol Chem 267: 10931-10934.
27. Bergers, G and Benjamin, LE (2003). Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3: 401-410.
28. Ohm, JE and Carbone, DP (2001). VEGF as a mediator of tumor-associated immunodeficiency. Immunol Res 23: 263-272.
29. Gabrilovich, D et al. (1998). Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 92: 4150-4166.
30. Jaffe, EA, Nachman, RL, Becker, CG and Minick, CR (1973). Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest 52: 2745-2756.
31. Yun, CO, Kim, E, Koo, T, Kim, H, Lee, YS and Kim, JH (2005). ADP-overexpressing adenovirus elicits enhanced cytopathic effect by induction of apoptosis. Cancer Gene Ther 12: 61-71.
32. Chartier, C, Degryse, E, Gantzer, M, Dieterle, A, Pavirani, A and Mehtali, M (1996). Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli. J Virol 70: 4805-4810.
33. Lee, OH et al. (1999). Sphingosine 1-phosphate induces angiogenesis: Its angiogenic action and signaling mechanism in human umbilical vein endothelial cells. Biochem Biophys Res Commun 264: 743-750.
34. Nicosia, RF and Ottinetti, A (1990). Modulation of microvascular growth and morphogenesis by reconstituted basement membrane gel in three-dimensional cultures of rat aorta: A comparative study of angiogenesis in matrigel, collagen, fibrin, and plasma clot. In Vitro Cell Dev Biol 26: 119-128.
35. Min, JK et al. (2004). Capsaicin inhibits in vitro and in vivo angiogenesis. Cancer Res 64: 644-651.
36. Choi, KJ et al. (2006). Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect. Gene Ther 13: 1010-1020.